Literature DB >> 15024181

Functional impairment of dendritic cells caused by murine hepatocellular carcinoma.

Wei-Chen Lee1, Yang-Jen Chiang, Hui-Chuan Wang, Min-Ru Wang, Shin-Ru Lia, Miin-Fu Chen.   

Abstract

Immunosuppression in tumor-bearing hosts may be a major obstacle in eradicating tumors. This study investigated whether hepatocellular carcinoma suppressed the functions of dendritic cells to escape tumor surveillance. Dendritic cells (DC), propagated from C57BL/10J mice, were cocultured with or without murine hepatoma Hepa1-6 cells to examine the influence of hepatocellular carcinoma on dendritic cells. The results revealed that dendritic cells cocultured with hepatoma cells expressed low levels of costimulatory molecules, and the stimulatory capacity was decreased. The antigen-specific cytotoxic effects of T cells activated by the DC cocultured with hepatoma cells were also decreased. In ex vivo studies, the maturation and function of dendritic cells propagated from tumor-bearing mice were suppressed. The suppressive effect of Hepa1-6 cells on dendritic cells could be partially reversed by neutralizing IL-10. In conclusion, the maturation and stimulatory function of DC are suppressed by hepatocellular carcinoma. IL-10 release may be one of the mechanisms employed by hepatocellular carcinoma to suppress dendritic cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15024181     DOI: 10.1023/B:JOCI.0000019779.56180.a2

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  32 in total

Review 1.  The Fas counterattack: cancer as a site of immune privilege.

Authors:  J O'Connell; M W Bennett; G C O'Sullivan; J K Collins; F Shanahan
Journal:  Immunol Today       Date:  1999-01

Review 2.  Reversal of tumor-induced immunosuppression: a new approach to cancer therapy.

Authors:  S Wojtowicz-Praga
Journal:  J Immunother       Date:  1997-05       Impact factor: 4.456

3.  In situ analysis of transforming growth factor-beta s (TGF-beta 1, TGF-beta 2, TGF-beta 3), and TGF-beta type II receptor expression in malignant melanoma.

Authors:  P Schmid; P Itin; T Rufli
Journal:  Carcinogenesis       Date:  1995-07       Impact factor: 4.944

4.  Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients.

Authors:  F Fu; Y Li; S Qian; L Lu; F Chambers; T E Starzl; J J Fung; A W Thomson
Journal:  Transplantation       Date:  1996-09-15       Impact factor: 4.939

5.  Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma.

Authors:  Q Chen; V Daniel; D W Maher; P Hersey
Journal:  Int J Cancer       Date:  1994-03-01       Impact factor: 7.396

6.  Bone marrow-derived dendritic cell progenitors (NLDC 145+, MHC class II+, B7-1dim, B7-2-) induce alloantigen-specific hyporesponsiveness in murine T lymphocytes.

Authors:  L Lu; D McCaslin; T E Starzl; A W Thomson
Journal:  Transplantation       Date:  1995-12-27       Impact factor: 4.939

7.  Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability.

Authors:  F Denizot; R Lang
Journal:  J Immunol Methods       Date:  1986-05-22       Impact factor: 2.303

8.  Altered immune responses in interleukin 10 transgenic mice.

Authors:  A Hagenbaugh; S Sharma; S M Dubinett; S H Wei; R Aranda; H Cheroutre; D J Fowell; S Binder; B Tsao; R M Locksley; K W Moore; M Kronenberg
Journal:  J Exp Med       Date:  1997-06-16       Impact factor: 14.307

9.  The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.

Authors:  J O'Connell; G C O'Sullivan; J K Collins; F Shanahan
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

10.  Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression.

Authors:  R de Waal Malefyt; J Haanen; H Spits; M G Roncarolo; A te Velde; C Figdor; K Johnson; R Kastelein; H Yssel; J E de Vries
Journal:  J Exp Med       Date:  1991-10-01       Impact factor: 14.307

View more
  2 in total

1.  Serum cytokine levels in patients with chronic hepatitis B according to lamivudine therapy.

Authors:  Younhee Park; Yongjung Park; Kwang-Hyub Han; Hyon-Suk Kim
Journal:  J Clin Lab Anal       Date:  2011-11       Impact factor: 2.352

Review 2.  Immunotherapeutic modulation of the suppressive liver and tumor microenvironments.

Authors:  Tim Chan; Robert H Wiltrout; Jonathan M Weiss
Journal:  Int Immunopharmacol       Date:  2011-01-15       Impact factor: 4.932

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.